| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29,4 M € | +5.0% | 28,0 M € | +0.9% | 27,8 M € | +0.7% | 27,6 M € | +23.5% | 22,3 M € | -3.4% | 23,1 M € | -17.8% | 28,1 M € | -0.8% | 28,4 M € | +2.1% | 27,8 M € | -2.8% | 28,6 M € | -3.7% | 29,7 M € | +1.1% | 29,4 M € | -6.9% | 31,5 M € | +2.0% | 30,9 M € | +4.5% | 29,6 M € | +8.0% | 27,4 M € | +1.4% | 27,0 M € | +5.4% | 25,6 M € | +5.8% | 24,2 M € | +0.4% | 24,1 M € | |
| EBITDA | 3,1 M € | -20.5% | 3,9 M € | -10.4% | 4,4 M € | -15.7% | 5,2 M € | +132.6% | 2,2 M € | -33.9% | 3,4 M € | -26.5% | 4,6 M € | +1.9% | 4,5 M € | -0.6% | 4,5 M € | -4.2% | 4,7 M € | -22.2% | 6,1 M € | +3.5% | 5,9 M € | -18.1% | 7,1 M € | +8.7% | 6,6 M € | +5.2% | 6,2 M € | +21.3% | 5,1 M € | +2.6% | 5,0 M € | -0.7% | 5,1 M € | +39.9% | 3,6 M € | +5.6% | 3,4 M € | |
| Operating profit | 2,8 M € | -22.4% | 3,6 M € | -11.1% | 4,1 M € | -19.7% | 5,1 M € | +156.1% | 2,0 M € | -35.0% | 3,0 M € | -28.8% | 4,3 M € | -1.1% | 4,3 M € | -2.1% | 4,4 M € | +8.4% | 4,1 M € | -28.4% | 5,7 M € | +1.6% | 5,6 M € | -18.3% | 6,8 M € | +9.1% | 6,3 M € | +16.9% | 5,4 M € | +24.5% | 4,3 M € | +0.5% | 4,3 M € | +4.8% | 4,1 M € | +47.8% | 2,8 M € | +60.2% | 1,7 M € | |
| Profit/loss | 2,0 M € | -23.9% | 2,6 M € | -13.3% | 3,0 M € | -12.9% | 3,5 M € | +167.2% | 1,3 M € | -37.3% | 2,1 M € | -27.4% | 2,8 M € | -2.6% | 2,9 M € | +3.9% | 2,8 M € | +10.6% | 2,5 M € | -30.3% | 3,6 M € | -0.1% | 3,6 M € | -17.4% | 4,4 M € | +10.2% | 4,0 M € | +15.7% | 3,5 M € | +25.8% | 2,8 M € | +0.7% | 2,7 M € | +8.8% | 2,5 M € | +53.4% | 1,6 M € | +86.0% | 881,8 k € | |
| Equity | 11,4 M € | +21.2% | 9,4 M € | -12.8% | 10,8 M € | +10.4% | 9,8 M € | -46.6% | 18,3 M € | +7.6% | 17,0 M € | -31.8% | 24,9 M € | +12.9% | 22,1 M € | +15.3% | 19,2 M € | +17.2% | 16,4 M € | +18.4% | 13,8 M € | +35.9% | 10,2 M € | +6.8% | 9,5 M € | +17.5% | 8,1 M € | +14.3% | 7,1 M € | +7.0% | 6,6 M € | +12.9% | 5,9 M € | -27.9% | 8,1 M € | +44.8% | 5,6 M € | +41.2% | 4,0 M € | |
| Total assets | 15,4 M € | -12.3% | 17,6 M € | +3.7% | 16,9 M € | -34.2% | 25,8 M € | +15.3% | 22,3 M € | -27.2% | 30,7 M € | +8.9% | 28,2 M € | +8.5% | 25,9 M € | +12.3% | 23,1 M € | +9.6% | 21,1 M € | +17.4% | 18,0 M € | +6.4% | 16,9 M € | -1.1% | 17,1 M € | +4.6% | 16,3 M € | +31.4% | 12,4 M € | -0.8% | 12,5 M € | +7.9% | 11,6 M € | -5.4% | 12,3 M € | -1.8% | 12,5 M € | +20.4% | 10,4 M € | |
| Cash | 2,8 M € | -42.6% | 4,9 M € | +35.4% | 3,6 M € | -76.9% | 15,6 M € | +17.6% | 13,3 M € | -32.1% | 19,6 M € | +33.0% | 14,7 M € | -3.7% | 15,3 M € | +8.5% | 14,1 M € | +38.1% | 10,2 M € | +3.1% | 9,9 M € | +52.1% | 6,5 M € | -17.5% | 7,9 M € | +27.0% | 6,2 M € | +49.0% | 4,2 M € | +68.1% | 2,5 M € | +35.1% | 1,8 M € | +226.2% | 562,0 k € | -68.5% | 1,8 M € | +158.6% | 690,9 k € | |
| Debts | 3,9 M € | -52.0% | 8,2 M € | +35.0% | 6,0 M € | -62.1% | 16,0 M € | +297.8% | 4,0 M € | -70.5% | 13,6 M € | +327.1% | 3,2 M € | -11.2% | 3,6 M € | +1.0% | 3,6 M € | -23.8% | 4,7 M € | +14.0% | 4,1 M € | -38.4% | 6,7 M € | -11.5% | 7,5 M € | -7.8% | 8,2 M € | +55.4% | 5,3 M € | -10.4% | 5,9 M € | +3.0% | 5,7 M € | +37.9% | 4,1 M € | -39.8% | 6,9 M € | +7.3% | 6,4 M € | |
| Staff | 31,1 | 28,1 | 28,3 | 28,9 | 28,3 | 29,2 | 32,3 | 31,9 | 28,6 | 27,2 | 26,7 | 25,9 | 24,4 | 22,1 | 23,2 | 23,6 | 23,3 | 24,3 | 25,7 | 28,1 | ||||||||||||||||||||
Public limited company · Evere · incorporated on 27/10/1961 · 31,1 ETP
Public limited company profitable and well capitalised. Cash position declining (-42.6%).
Solid counterparty for a standard engagement.
Melisana is a Public limited company incorporated in 1961. Its main activity is: Wholesale of pharmaceutical goods. Its registered office is in Evere. It employs on average 31,1 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette